The war against drug-resistant bacteria just gained another soldier—and a meaningful cash infusion.
Centauri Therapeutics, a British biotech tucked away in the pharmaceutical hub of Alderley Park, Cheshire, has closed an additional £6 million from the AMR Action Fund, pushing its extended Series A round to £30 million. The February 24 announcement marks a notable vote of confidence in the company's unconventional approach to a problem that has vexed the pharmaceutical industry for decades: how to make fighting superbugs financially viable.
It's a question that grows more pressing by the year. The company's own 2022 fundraising materials pointed to Lancet data estimating 4.95 million deaths linked to bacterial antimicrobial resistance in 2019 alone. Traditional antibiotics, once the pharmaceutical industry's bread and butter, increasingly fail against evolving pathogens—yet developing new ones rarely pencils out for shareholders.
A Platform Play in a Crowded Field
Centauri's pitch centers on what it calls Alphamer technology, acquired from Altermune Technologies back in 2016. The science is elegant in theory: rather than developing entirely new antibodies, the platform uses modular molecular constructs to redirect a patient's existing antibody arsenal toward bacterial invaders. Think of it as reprogramming the body's immune system to recognize threats it previously ignored.
The lead candidate, CTX-187—previously known in company documents as ABX-01—emerged from this platform in March 2025. CEO Jennifer Schneider and her team have positioned it as a dual-threat molecule: it activates complement pathways and triggers opsonophagocytosis (the process by which immune cells engulf marked bacteria), while also exerting direct antibacterial effects. Whether that combination proves meaningfully superior to existing approaches remains an open question, one Phase I trials now underway should begin to answer.
The company has at least bought itself time to find out. Beyond this latest equity round—which builds on an initial £24 million close in January 2022 led by Boehringer Ingelheim Venture Fund, Evotec SE, and Novo Holdings' REPAIR Impact Fund—Centauri has pulled in $12.3 million in non-dilutive funding from CARB-X since 2019. That includes a $5.1 million award last July earmarked specifically for pushing CTX-187 toward human testing.
Follow-the-Money Signals
The AMR Action Fund's involvement carries particular weight. Launched as a more than $1 billion initiative backed by major pharmaceutical players and the European Investment Bank, the fund has set an ambitious target: bring two to four new antibiotics to market by 2030. In an industry where antibiotic development timelines routinely stretch a decade or longer, that's an aggressive bet.
Dr. Henni-Karoliina Ropponen from the fund will now take a board seat at Centauri—standard practice for strategic investors, but also a signal that the fund sees this technology as among its better horses in what remains a long race.
Centauri moved to shore up its clinical capabilities last year, appointing Dr. Debra Barker as Chief Medical Officer in July 2025. The hire telegraphs where the company's focus lies now: navigating the regulatory gauntlet from Phase I completion through Phase II expansion, the stage where many promising biotechs stumble.
The company also snagged grant support from Innovate UK's PACE-AMR program in 2024, adding to a funding portfolio that, for a relatively early-stage venture, suggests institutional appetite for alternative antimicrobial approaches.
The Sobering Economics of Antibiotics
What makes Centauri's trajectory worth watching isn't just the science—it's whether the funding model can actually work.
The pharmaceutical industry largely abandoned antibiotic development years ago, not because the need disappeared but because the math didn't work. New antibiotics get reserved for last-resort use to slow resistance, meaning low prescription volumes and limited revenue potential. Vaccines and chronic disease treatments simply offer better returns.
Funds like AMR Action and programs like CARB-X represent an attempt to patch that market failure with outside capital, essentially subsidizing development that private markets alone won't support. Whether that approach can sustainably deliver new drugs—and whether Centauri's Alphamer platform offers genuine advantages over competing technologies—are questions that won't be answered in press releases.
For now, the company has secured the runway to find out. And in a field where failures outnumber successes by wide margins, that counts as progress.
